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Effector mechanisms of influenza-specific antibodies: neutralization and beyond
Federica Sicca, Sam Neppelenbroek and Anke Huckriede
Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
ABSTRACT
Introduction: Antibodies directed against influenza virus execute their protective function by exploit-
ing a variety of effector mechanisms. Neutralizing antibodies have been thoroughly studied because of
their pivotal role in preventing influenza virus infection and their presence in host serum is correlated
with protection. Influenza antibodies can also exploit non-neutralizing effector mechanisms, which until
recently have been largely overlooked.
Areas covered: Here, we discuss the antibody response to influenza virus in its entire breadth.
Neutralizing antibodies mostly target variable epitopes on influenza surface proteins and interfere
with virus binding, fusion, or egress. Non-neutralizing antibodies instead usually target conserved
epitopes which can be located on surface as well as internal proteins. They drive viral clearance via
interaction of their Fc region with components of the innate immune system such as immune effector
cells (e.g. NK cells, macrophages) or the complement system.
Expert commentary: Recent research has unraveled that influenza-specific antibodies target multiple
proteins and make use of diverse effector mechanisms. Often these antibodies are cross-reactive among
virus strains of the same subtype or even between subtypes. As such they are induced early in life and
are boosted by regular encounters with virus or vaccine. Designing strategies to optimally exploit these
pre-existing antibodies may represent the key for the development of new broadly protective influenza
vaccines.
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Influenza is a major public health problem as it is associated
with high rates of morbidity and mortality worldwide. Type A
and type B influenza viruses cause this respiratory tract infec-
tion which is characterized by sudden onset of symptoms such
as high fever, headache, myalgia, malaise, and a sore throat
[1]. The majority of individuals infected with influenza virus
recover without medical attention. However, young children,
the elderly, and chronically ill people are groups at risk for
developing severe illness, which can be fatal.
Influenza viruses are enveloped viruses which belong to
the Orthomyxoviridae family. The two clinically relevant gen-
era of the Orthomyxoviruses are influenza virus A and influ-
enza virus B. Among the influenza A viruses, different subtypes
can be distinguished based on the subtypes of hemagglutinin
(HA) and neuraminidase (NA) [2]. So far, 18 different subtypes
of the HA protein (H1-H18) and 11 different subtypes of the
NA protein (N1-N11) have been identified [3]. Influenza B
viruses form two lineages, the B/Victoria/2/87-like lineage
and the B/Yamagata/16/88-like lineage, but are not further
divided into subtypes [4]. The genome of influenza viruses is
composed of single-stranded RNA organized in separate seg-
ments [5]. This genome make-up enables rapid evolution of
influenza virus since replication of RNA is highly error-prone
resulting in frequent point mutations. Moreover, the segmen-
ted nature of the genome enables the swap of entire
segments if two different viruses infect a given cell simulta-
neously. This phenomenon is observed mainly for influenza A
viruses which circulate in a number of animal species, in
contrast to influenza B viruses which are with few exceptions
restricted to humans. If point mutations or segment swap
affect the HA glycoprotein, the major antigen of influenza
virus, they can lead to antigenic drift and antigenic shift,
respectively, thus enabling the virus to escape immune
responses evoked by prior infection or vaccination [6,7].
Cellular as well as humoral immune mechanisms are
involved in the defense against influenza virus infection.
Cellular immunity, in particular CD8+T-cell-mediated immu-
nity, mainly targets internal viral proteins like nucleoprotein
(NP), matrix protein 1 (M1), or the polymerase proteins (PA,
PB1, PB2), which are rather conserved across different influ-
enza virus strains [8,9]. In contrast, influenza-specific antibo-
dies mainly target the viral surface proteins, HA and NA, of
which the most exposed parts are highly variable. Yet, anti-
bodies directed against conserved regions on the HA head
and particularly the HA stem as well as antibodies against a
range of other more conserved viral proteins can also be
found in recently infected individuals (Figure 1) [10]. These
antibodies have lately been shown to play an important role in
protection against influenza virus infection [9].
Antibodies directed against influenza virus make use of a
variety of effector mechanisms [11,12]. Antibody-mediated
neutralization is the most important mechanism and can
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prevent influenza virus infection of host cells. The ability of
antibodies to neutralize influenza virus is correlated with pro-
tection and has, therefore, been studied thoroughly [13,14].
The majority of neutralizing antibodies is directed against the
highly variable head region of the HA molecule. As such the
activity of these antibodies is highly strain-specific. Besides
neutralization, antibodies directed against influenza virus can
also make use of effector mechanisms, which do not interfere
with the initial infection steps but elicit their protective func-
tion later in the viral life cycle [15]. More complex immune
interactions are needed for the non-neutralizing antibodies to
work. In contrast to neutralizing antibodies which target the
variable HA molecule, non-neutralizing antibodies can be
directed to a variety of influenza virus proteins. While recogni-
tion of the target protein is mediated by the variable parts of
the antibody molecules, their biological function is deter-
mined by the constant parts of the heavy chains, the Fc part.
Accordingly, the class and subclass of the antibodies are very
important for the type of effector functions they can
engage in.
Neutralizing antibodies are highly effective in protecting
from influenza infection but at least the classic neutralizing
antibodies detected in hemagglutination inhibition assays are
not effective against newly emerging influenza virus strains
since they are strain-specific. Non-neutralizing antibodies, on
the other hand, often target more conserved epitopes.
Although they cannot prevent initial infection, they may pro-
vide a certain level of protection also against newly emerging
influenza virus strains [16,17]. A thorough understanding of
the different types of influenza-specific antibodies, their tar-
gets and their working mechanisms might thus be useful for
the design of broadly protective vaccines. This review will give
an overview of antibody-mediated effector mechanisms
involved in protection against influenza virus.
2. Working mechanisms of neutralizing antibodies
The HA and NA glycoproteins are the most immunogenic
proteins of influenza A and B and, therefore, represent the
main target for neutralizing antibody responses elicited by
infection or vaccination. Most antibodies reacting with influ-
enza virus are directed against the easily accessible globular
head of HA [18]. The globular head also harbors the receptor-
binding domain and engages with sialic acid residues on
target cells [19]. After endocytosis of the virus, the stem region
of HA mediates the low pH-triggered fusion of the viral and
the endosomal membrane by which the viral genome gets
access to the cytosol [10,19–21]. NA on the other hand is a
tetramer that has enzymatic function; it removes sialic acid
residues from the surface of infected cells, thereby allowing
the release of virions after the budding process.
Neutralizing antibodies can prevent binding of the virus to
the sialic acid receptor, can hamper the fusion process, or can
interfere with the release of newly formed viral particles
(Figure 2). Not each of these processes is neutralizing in the
sense that initial entry of the target cell is prevented, however,
all reduce virus spread in the first infection cycle. Traditional
hemagglutination inhibition assays measure only those anti-
bodies which interfere with binding of the virus to the host
cell. Accordingly, neutralizing antibodies targeting other pro-
cesses have long been overlooked.
2.1. Neutralizing antibodies targeting the HA head
Antibodies against the HA head usually result in strain-specific
protection since they bind highly variable epitopes. It has been
shown that these antibodies interfere with the entry of influenza
virus by inhibiting the binding between HA and sialic acid. As
such they represent the main type of antibodies detected in a
classical hemagglutination inhibition assay [22–25]. Neutralizing
antibodies directed against the HA head nevertheless have also
been shown to be able to interfere with the egress of virions from
an infected cell [22,26]. Likely, egression of virions is inhibited by
cross-linking of newly formed virions to each other and to HA on
the cell membrane [22]. These latter antibodies have for a long
time been overlooked given that they cannot be detected with
classical neutralization assays [25].
In contrast to these strain-specific anti-HA head neutraliz-
ing antibodies, some neutralizing antibodies directed against








Figure 1. Targets of influenza-specific antibodies. (a) Antibody-targeted protein domains on virions. Antibodies may target the head or stem region of HA or the NA
protein. (b) Antibody-targeted protein domains on infected cells. On the membrane of infected cells, antibodies can access the HA head and stem, NA, M2 and
possibly NP.
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subtypes of influenza virus [27–29]. Antibodies that are able to
neutralize several strains of influenza virus are called broadly
neutralizing antibodies (bNAbs). bNAbs directed against the
HA head bind to conserved regions of this domain, for exam-
ple the pocket of HA which binds sialic acid [10]. However, the
epitope-binding region of an antibody is larger than this
pocket and these antibodies will, therefore, usually also be in
contact with variable parts of the HA molecule [18]. bNAbs
against the HA head are rarely found, possibly because the HA
evolved in such a way that the receptor-binding pocket, which
needs to be conserved and is therefore vulnerable for immune
recognition, is kept small and is surrounded by highly variable
regions which allow immune escape [18,30].
2.2. Neutralizing antibodies targeting the HA stem
Neutralizing antibodies directed against the stem part of HA
are far less commonly found after vaccination or exposure to
virus than anti-HA head neutralizing antibodies [30]. The stem
of HA, although more conserved, is generally less immuno-
genic than the head. One possible reason is that the bulky
head of the HA protein impairs the accessibility of the stem for
antibodies [31]. However, low amounts of anti-HA stem neu-
tralizing antibodies can be detected in humans after infection
by influenza viruses or after vaccination, with infection being
more effective than vaccination in inducing this type of anti-
bodies [30,32].
Antibodies against the HA stem interfere with fusion of the
virus with the endosomal membrane following internalization of
the virus by the cell and lowering of the endosomal pH [22,33].
For the fusion process to occur, a network of at least 3–5 neigh-
boring HA proteins inserting their fusion peptides into the endo-
somal membrane is needed [34–36]. HA stem-directed
neutralizing antibodies have the ability to prevent the pH-
induced exposure of the HA fusion peptide and thereby disrupt
the formation of the network of HA proteins engaging with the
endosomal membrane [24,33,37]. About 60% of the HA proteins
has to be covered with antibodies to effectively prevent fusion of
the viral and endosomal membrane [33].
Inhibition of fusion is the main effector mechanism of anti-
HA stem-directed neutralizing antibodies in the protection
against influenza virus, however, some of these antibodies
are also able to inhibit the cleavage of HA0 [22]. HA0 is the
precursor of HA1 and HA2 and cleavage of HA0 into HA1 and
HA2 is needed to enable newly formed virions to successfully
infect new host cells [38]. Proteases on the surface of the host
cell are responsible for this cleavage [39]. Some HA stem
neutralizing antibodies are able to bind HA0 close to the
cleavage site on the surface of an infected host cell and can
thereby prevent membrane-bound proteases from cleaving
HA0 [22]. Moreover, HA stem neutralizing antibodies have
been shown to be able to inhibit egress of newly produced
viral particles [26]. The HA stem neutralizing antibodies can,
thus, be protective by the inhibition of membrane fusion, the
inhibition of HA0 cleavage, and inhibition of viral egress from
the infected cells.
The breadth of cross-reactivity against different strains,
subtypes, or types of influenza virus is dependent on the
level of conservation of the epitope that these antibodies
bind [10]. Most HA stem-specific bNAbs are able to bind to
different subtypes of influenza virus within one of the two
phylogenetic groups of influenza virus type A [24]. Anti HA
stem bNAbs are most frequently found for group 1 viruses
[10]. Only a few of the bNAbs directed against the HA
stem are found to neutralize different subtypes of influ-
enza within group 2 [40]. Some HA stem bNAbs have the
?
influenza infected cell
Figure 2. Mechanisms of neutralizing antibodies. ① Preventing interaction between virus and sialic acid receptor. ② Preventing fusion of viral and endosomal
membrane. ③ Preventing release of newly formed viral particles. ④ Preventing cleavage of HA0 to HA1 and HA2 by membrane bound proteases.
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ability to bind different strains of both phylogenetic
groups, however these are rarely found [10]. These anti-
bodies have the ability to do this because they have multi-
ple binding modalities, so they can bind multiple related
structures on the HA-stem of different subtypes [10]. A
bNAb that can bind to both different influenza virus type
A strains as well as influenza virus type B strains has also
been described [41].
Compared with the highly variable epitopes located in the
HA head domain, the mutation rate of the HA stem region is
rather low. Nevertheless, even in the case of stem-binding
antibodies, we witness the phenomenon of influenza immune
escape [42,43]. Amino acid changes allowing immune escape
can result in loss of recognition by antibodies. For example, it
has been described that the stem part of HA can undergo
antigenic drift when HA stem directed bNAbs are present [44].
The drifted viruses regained their ability to infect host cells in
the presence of bNAbs. Yet, it has also been shown that
influenza A virus can escape antibody neutralization via muta-
tions that do not alter antibody binding. Chai et al. described a
mechanism by which mutations enhanced the fusion ability of
the virus [43]. These mutations led to reduced binding of the
antibodies at low pH, as encountered in the endosome after
virus internalization. At the same time, the mutated HA could
achieve its fusion-active conformation at higher pH than the
wildtype variant thus extending the pH window under which
fusion could take place. Thus, immune escape from bNAbs
directed against the HA stem does occur. However, most of
these mutations negatively affect the fitness of the virus and
accordingly the importance of these immune escape mechan-
isms in vivo remains unclear and needs to be further investi-
gated. Moreover, while single point mutations easily prevent
binding of antibodies to the globular head of the HA molecule
thus leading to immune escape, single point mutations in the
stem region seem to only moderately reduce antibody bind-
ing and several mutations are necessary to achieve immune
escape[45].
2.3. Antibodies targeting NA
The NA protein is important at different stages of the infection
process. Due to its sialidase activity, NA allows the virus to
reach the target cells by cleavage of sialic acids from respira-
tory tract mucins [46]. Also, NA makes budding of new virions
possible by preventing virions to remain bound to sialic acid
residues on the host cell. In addition, NA prevents aggregation
of newly formed virions, caused by the interaction of the HA
on one virion with sialylated glycans on a second one [46].
Antibodies targeting NA come into play when HA-binding
antibodies are absent or are unable to prevent infection [47].
Immunity directed against the influenza virus NA has been
shown to provide protection against viral infection in animal
models [48–51]. Furthermore, several studies have demon-
strated that NA-based immunity also correlates with protection
from influenza virus infection and disease in humans [46,52].
Recently, Rajendran et al. assessed the breadth, functionality,
and isotype/subtype usage of anti-NA antibodies in children,
adults, and the elderly. They found that anti-NA titers increase
with age, but the magnitude of the response is subtype
dependent and appears to be low for N1, whereas it is higher
and cross-reactive for N2 and influenza B virus NA [46].
Recent findings demonstrate that influenza virus infection
induces NA-reactive B cells to an equal or even higher level
than HA-reactive B-cells. In contrast, current influenza vaccines
poorly display key NA epitopes and consequently rarely
induce NA-reactive B-cells [53]. Since NA-binding antibodies
appear to be broadly reactive to virus strains which circulated
in humans in the past, a vaccine eliciting broadly reactive
antibodies against NA would be greatly beneficial [53]. Given
the fact that many questions remain open regarding neurami-
nidase-based immunity, a neuraminidase focus group
(NAction) was formed at a Centers of Excellence for Influenza
Research and Surveillance meeting at the National Institutes of
Health in Bethesda, MD, to answer these questions and fill in
the knowledge gaps in this field with the goal to implement
better influenza vaccines [54].
3. Working mechanisms of non-neutralizing
antibodies
Traditionally, the ability of antibodies to directly neutralize
influenza virus was considered as the most important function
in the protection against influenza virus. However, recent
findings show the importance of other antibody-mediated
effector mechanisms, which are also contributing to protec-
tion against influenza virus but have so far been largely over-
looked [55,56]. Given the fact that non-neutralizing antibodies
often target more conserved epitopes of influenza virus pro-
teins they may be of particular importance for the develop-
ment of vaccines with broadly protective function. Three
effector mechanisms that can be induced by non-neutralizing
antibodies are known to contribute to protection against
influenza virus. These effector mechanisms are antibody-
dependent cellular cytotoxicity (ADCC), antibody-dependent
cellular phagocytosis (ADCP), and antibody-dependent com-
plement deposition (ADCD) (Figure 3) [10,11].
In contrast to neutralizing antibodies which exert their func-
tion via the variable part of the antibody molecule alone, the
effect of non-neutralizing antibodies is dependent on both the
variable region and the Fc region of the antibody [57]. The Fc
region has the ability to interact with other components of the
immune system, at least when the antibody is bound to an
antigen. Five classes of antibodies can be distinguished based
on the structure of their Fc region, namely, IgA, IgD, IgE, IgG,
and IgM [58]; among these IgG and IgM are particularly impor-
tant for non-neutralizing antibody effector functions. IgG can be
further subdivided into four subclasses (IgG1, IgG2, IgG3, and
IgG4 in humans), which differ in their Fc region and accordingly
in their biological characteristics. IgG3 is considered as the IgG
antibody subclass with highest functional potency when com-
pared to the other IgG subclasses [59]. Furthermore, according
to recent results not only the Fc region itself but also its
glycosylation status is important for the functional potency of
non-neutralizing antibodies [11,50].
Non-neutralizing antibodies can work by binding of the Fc
region to specific Fc receptors present on a variety of immune
cells including NK cells, macrophages, and neutrophils [57]. After
binding, these immune cells can be activated and help in the
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protection against influenza virus. Six different Fc receptors,
either activating (FcγRI, IIA, IIC, IIIA and IIIB) or inhibitory
(FcγRIIB1/B2), have been described in humans [60].
Alternatively, non-neutralizing antibodies can activate the com-
plement system via the classical pathway. Thus, non-neutralizing
antibodies have an important role in connecting innate and
adaptive immunity mechanisms [10].
3.1. Antibody-dependent cellular cytotoxicity (ADCC)
Cells infected with influenza virus present viral proteins,
mostly HA and NA, on their surface because new virions are
being formed and will eventually bud from the cell mem-
brane. Influenza-specific IgG can bind to the viral proteins on
the cell surface, thus opsonizing infected cells. Subsequently,
Fc gamma receptor IIIa (FcγRIIIa), expressed by innate effector
cells like natural killer (NK) cells, monocytes and macrophages,
binds to the Fc region of the bound IgG. Crosslinking of
FcγRIIIa molecules on the surface of the effector cell leads to
phosphorylation of the immunoreceptor tyrosine-based acti-
vation motif (ITAM) and subsequent activation of a Ca2+
dependent signaling pathway. Following these events, NK
cells release cytotoxic factors that cause the death of the
infected cell (perforin and proteases known as granzymes) as
well as the production of antiviral cytokines like IFNγ , TNFα
and chemokines. These antiviral cytokines and chemokines
contribute further to a decrease of viral replication [17].
Influenza ADCC is epitope-dependent as demonstrated by
DiLillo et al. in 2014 when they examined the importance of
epitope localization for influenza-specific ADCC using a panel
of monoclonal Abs (mAbs) [56]. The authors showed that
bNAbs targeting the highly conserved HA stem protected
mice from lethal influenza challenge with H1N1 viruses
through a mechanism that involved Fc-FcγR interactions. In
contrast, strain-specific mAbs against the variable head
domain of HA were equally protective in the presence or
absence of FcγR interactions, which suggested that they pro-
vided protection in an FcγR-independent manner [16,56]. The
group further demonstrated that ADCC was necessary for in
vivo protection and that the antiviral activity of HA stem
bNAbs was mediated through activating FcγRs [56].
In a subsequent study, DiLillo et al. screened a panel of 13
anti-HA mAbs (bNAbs and non-neutralizing Abs, against both
the stalk and head domains) and showed that all classes of
broadly binding anti-HA mAbs required Fc-FcγR interactions to
provide protection in vivo [61]. Interestingly, only antibodies
targeting the HA stem but not antibodies targeting the HA
head were found capable of mediating ADCC. In fact, anti HA-
head antibodies when mixed with anti-stem antibodies
appeared to hamper ADCC induced by the latter [62]. It was
later demonstrated that the receptor-binding domain of HA

















Figure 3. Mechanisms of non-neutralizing antibodies. (a) Antibody-dependent cellular cytotoxicity (ADCC): Influenza-specific IgG binds to the viral proteins on the
cell surface, thus opsonizing infected cells. Subsequently, Fc gamma receptor IIIa (FcγRIIIa), expressed by innate effector cells like NK cells, binds to the Fc region of
the bound IgG while at the same time sialic acid receptors on the NK cells engage HA on the infected cell. Thus activated NK cells release cytotoxic factors that cause
the death of the infected cell as well as antiviral cytokines (IFNγ, TNFα) and chemokines [70]. (b) Antibody-dependent cellular phagocytosis (ADCP) of infected cells
and (c) viral particles. After opsonization of a microbe or an infected cell by antibodies, phagocytes like monocytes, macrophages, neutrophils, and dendritic cells
recognize the antibodies that are bound to the foreign particles with their antibody receptors. Phagocytes will then engulf and destroy the opsonized cells or viral
particles [72,78]. (d) antibody-dependent complement deposition (ADCD); complement-dependent lysis (CDL) and complement-dependent opsonophagocytosis of
infected cells and (e) viral particles; Following the classic pathway, complement factor C1q binds to antibody opsonized viral particles or infected cells. In the
subsequent cascade of events, C1q deposition enables the generation of anaphylatoxins like C3a and C5a, formation of opsonins like C3b and C5b which remain
bound to the membrane and stimulate phagocytosis, and ultimately formation of a membrane attack complex (MAC) which can destroy virus particles [84,86].
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the surface of effector cells to optimize effector cell activation
in the context of ADCC [62,63]. In particular, broadly reactive
mAbs seem to require two molecular contacts, possibly to
stabilize the immunologic synapse and fully induce the anti-
viral activity of the innate effector cell. The first contact is the
interaction between the Fc of a mAb bound to HA with the
FcγR of the effector cell, and the second contact is the inter-
action between the HA on the infected cell and its sialic acid
receptor on the effector cell [63].
It is very likely that in the natural situation there is not only
one type of antibody but instead an ensemble of different
types of antibodies against influenza antigens. He et al.
showed that interactions among antibodies that bind viral
glycoproteins of varying specificities regulate the extent to
which ADCC is induced [64]. They also show that interactions
among antibodies that bind to discrete epitopes on the same
antigen can influence the induction of Fc-dependent effector
functions. Their observations imply that when sufficient neu-
tralizing antibodies are present, ADCC is inhibited, and neu-
tralization is the primary mode of protection. However, when
neutralizing antibodies are absent or limited, bnAbs targeting
the HA stalk domain engage effector cells to stimulate ADCC
and thereby limit the spread of infection.
Antibodies to conserved, internal viral proteins, such as NP,
also seem to contribute to protection against influenza [65].
ADCC-mediating Abs to internal viral proteins such as NP and
M1/2 are induced by influenza infection and vaccination. These
conserved internal proteins can be found on the surface of
infected cells in vitro and several lines of evidence support the
fact that antibodies against NP andM2 are involved in ADCC [66].
ADCC-mediating antibodies to NP have recently been shown to
be induced through vaccination of children with seasonal inacti-
vated influenza vaccine [67]. Moreover, recent work by
Vanderven et al. demonstrates that healthy and influenza
infected human individuals have anti-NP antibodies that can
cross-link FcγRIIIa and activate human NK cells [68]. Finally, it
has been found in ADCC assays that sera from healthy humans
containing anti-NP antibodies can induce robust NK cell activa-
tion against NP-expressing and virus-infected cells [67].
Another conserved influenza protein found on the surface
of infected cells is M2. Antibodies against this protein were
found to be protective in mice. It was demonstrated that
passive immunotherapy with a fully human mAb targeting
the M2 protein in mice resulted in significant protection
from lethal infection. Importantly, ADCC and complement
were proven to be required for non-neutralizing anti-M2 anti-
body-mediated protection in vivo [69]. Another study showed
that a human mAb targeting the M2 protein (Ab1-10) was
capable of activating NK cells and mediating ADCC in vitro.
In particular, it was shown that the above-mentioned mAb is
capable of mediating ADCC against cells transfected with the
M2 protein and also against influenza-infected cells [70].
3.2. Antibody-dependent cellular phagocytosis (ADCP)
Phagocytosis is an important immunological process in which
phagocytes ingest microbes and infected cells [71]. One spe-
cific form of phagocytosis is ADCP. The first step in ADCP is
opsonization of a microbe or an infected cell by antibodies
[71]. After opsonization, phagocytes recognize the antibodies
that are bound to the foreign particles with their antibody
receptors, in particular the Fcγ receptors CD32 (FcγRIIA) and
CD64 (FcγRIA) and the Fcα receptor CD89 [72]. The most
important phagocytes involved in ADCP are monocytes,
macrophages, neutrophils, and dendritic cells [71]. When the
phagocytes recognize an opsonized viral particle or opsonized
infected cell with their antibody receptor, phagocytes will
engulf them in a phagosome [73]. Phagosomes mature and
then fuse with lysosomes. These lysosomes contain different
enzymes and superoxide that are able to destroy the content
of the phagolysosomes [74]. In this way not only foreign
particles but also opsonized infected cells can be destroyed.
ADCP is one of the important antibody-induced effector
mechanisms that contribute to protection against influenza.
Already in 2001 Huber et al. investigated the role of opsonopha-
gocytosis in protection against lethal influenza virus infection
using FcγR −/−mice [75]. They showed that FcγR −/− mice were
highly susceptible to influenza infection, even in the presence of
anti-influenza Abs from immune FcγR +/+ mice. NK cells were
not required for Ab-mediated protection, but macrophages from
FcγR +/+ mice could actively take up opsonized virus particles
indicating that Fc receptor-mediated phagocytosis can be of
major importance in clearing influenza virus infections. Further
indications for a role of ADCP in the defense against influenza
came from studies in which live influenza A virus particles and
influenza protein-coated fluorescent beads were opsonized with
antibodies and their uptake into a monocytic cell line was mea-
sured. Both serum IgG from healthy adults and from pooled
intravenous immunoglobulin (IVIG) preparations was found to
contain antibodies capable of mediating ADCP of beads coated
with HA from multiple virus subtypes [76]. It is likely, as the
authors suggest, that the numerous exposures of human adults
to influenza (through previous infection or vaccination) cause
low levels of cross-reactive antibodies capable of mediating
ADCP, which are boosted by subsequent heterologous infections
[77]. These results did not prove, although, that antibodies can
indeed confer protection against influenza infection bymeans of
ADCP. Evidence for the protective potential of ADCP-inducing
antibodies, at least in the mouse model, comes from an in vivo
study by Dunand et al. These authors showed that some broadly
cross-reactive non-neutralizing mAbs protected mice through
Fc-mediated effector cell recruitment and in particular they did
so exclusively through ADCP and not through ADCC or ADCD
[55]. Several antibodieswith different specificities have the ability
to mediate ADCP among which even bNAbs directed against the
HA stem [55,78,79].
Digging deeper in the analysis of influenza-specific ADCP, it
was demonstrated that alveolar macrophages (AMφ) are criti-
cally involved in ADCP induced by murine as well as human
monoclonal Abs in vivo and are necessary for conferring opti-
mal protection against homologous and heterologous virus
challenge [79]. Both non-neutralizing Abs and bNAbs can
mediate ADCP of opsonized virus and are able to activate
AMφ to establish a pro-inflammatory environment [79].
Interestingly, Wong et al. recently documented in mice that
with aging, AMφ exhibit an impaired ability to limit lung
damage during influenza viral infection [80]. It is tempting to
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speculate that impairment of ADCP is one reason for this
phenomenon.
Apart from AMφ, other innate effector cell populations can
be involved in ADCP-mediated protection against influenza.
Mullarkey et al. focused on neutrophils, which are the most
abundant subset of blood leukocytes and which express both
activating and inhibitory FcγRs [78]. The group analyzed the
interplay between HA stem-specific IgG, Fc-FcγR engagement,
and neutrophil effector functions. They demonstrate that
human and mouse monoclonal HA stem-specific IgG antibo-
dies are able to induce the production of reactive oxygen
species (ROS) by neutrophils and that this phenomenon is
dependent on FcR engagement and phagocytosis. They also
showed that this was not the case for HA head-specific anti-
bodies, confirming once again how the ability of HA stem-
specific antibodies to mediate Fc-FcγR receptor engagement is
epitope-dependent [78].
3.3. Antibody-dependent complement deposition
(ADCD)
The complement system is made of soluble and membrane
proteins, which are found ubiquitously in the blood and
tissues of mammals. These proteins interact with each other
and with other components of the immune system building
up a series of effector proteins that contribute to the elim-
ination of various pathogens, including influenza virus.
Complement activation can occur through three pathways,
which are called the classical, lectin, and alternative path-
ways, and it represents an important link between innate and
adaptive immunity [81]. Noteworthy, according to textbook
knowledge, only the classical pathway depends on the pre-
sence of antibodies against the pathogen. The central events
in complement activation are proteolysis of the complement
protein C3 into C3a and C3b, and later proteolysis of C5 into
C5a and C5b. C3a and C5a serve as ‘anaphylatoxins’ and help
in recruitment of leukocytes. C3b and C5b are opsonins
which remain bound to the pathogen and enhance phago-
cytosis by neutrophils and macrophages. In addition, C5b
enables deposition of additional components of the comple-
ment system which eventually results in formation of the
membrane attack complex [11,82].
The fact that human sera contain antibodies capable of
neutralizing influenza virus by engaging the classical pathway
of the complement system was shown as early as 1982 by
Beebe et al. [83]. Later studies confirmed that IgG and IgM
bound to influenza virions activate the classical pathway of
complement (C1) resulting in neutralization of infectivity
[84,85]. The alternative pathway was found to be also acti-
vated, yet, was on its own not capable of neutralizing the
virus. Interestingly, activation of the alternative pathway also
required IgG suggesting an interplay between the classical
and the alternative pathways [83]. In-line with these results,
a later study demonstrated that protection of mice from influ-
enza A(H1N1)pdm09 infection required an intact classical and
alternative pathways, both requiring IgG for activating influ-
enza neutralizing functions. Synergy between the two path-
ways was found to be critical to contain the infection [85].
Further investigations gave a somewhat complicated picture.
Influenza virus H1N1pdm09 appeared to be resistant to lectin
pathway-mediated neutralization as well as to alternative
pathway-mediated neutralization in the absence of antibodies.
In contrast, seasonal influenza A H3N2 virus was found to be
susceptible to alternative pathway-mediated neutralization
even in the absence of antibodies. The difference between
the strains could be attributed to the fact that on H3N2 virus
C3b deposition could take place through covalent linkage of
C3b to HA and/or NA while HA/NA of H1N1pdm09 virus did
not support C3b binding [85].
The complement system is not only able to neutralize
virus particles but also involved in the lysis of infected
cells in humans. Vaccination with standard trivalent-inacti-
vated influenza vaccine was found to increase levels of
antibodies capable of mediating complement-dependent
lysis (CDL) of influenza virus-infected cells in vitro, though
fold increases were moderate [86]. Although direct proof is
lacking, these antibodies can potentially contribute to clear-
ance of both viral particles and infected cells in vivo. Further
analysis of infection or vaccination-induced human antibo-
dies with the ability to induce CDL revealed that most of
these antibodies also have virus-neutralizing capacity [87].
However, not all neutralizing antibodies were able to med-
iate CDL. Both HA head neutralizing antibodies and HA stem
neutralizing antibodies were found to be able to mediate
CDL. The HA stem neutralizing antibodies were, however,
more cross-reactive and, thus, were able to induce CDL of
different strains of influenza virus.
Many viruses make use of complement evasion strategies
by encoding proteins that bind and inhibit or sequester com-
plement components. Evidence exists that the matrix (M1)
protein prevents complement-mediated neutralization of
influenza virus in vitro by binding C1q and blocking the inter-
action between C1q and IgG [88].
4. Conclusion
We reviewed here the main effector mechanisms of antibo-
dies directed against influenza virus. Antibodies can confer
protection against influenza through Fc-independent or Fc-
dependent mechanisms. Fc independent antibodies directly
neutralize the virus by interfering with the process of virus
entry, fusion, or egress. Mainly antibodies against HA and
NA are involved in direct neutralization of the virus [24].
Since most directly neutralizing antibodies target highly
variable epitopes, they are usually strain-specific. Fc-depen-
dent antibodies do not act via direct neutralization but
rather activate cell-dependent or complement-dependent
effector mechanisms [17]. Non-neutralizing antibodies can
interact through their Fc part with FcγR located on the
membrane of immune effector cells thus causing ADCC or
ADCP, or can activate the complement system via the clas-
sical pathway. Antibodies that act through these mechan-
isms can be directed against HA, NA, M2, or NP. Therefore,
they can target variable as well as conserved epitopes of
influenza viruses [67,70].
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5. Expert commentary
Fostered by research initiated after the threat of an H5N1
pandemic in the early 2000s and the 2009 H1N1 pandemic,
our knowledge on antibody-mediated immune responses to
influenza has increased enormously in recent years. Three
observations which are of particular importance in this context
are described in the following.
The first observation was the detection of broadly neutra-
lizing antibodies, thus antibodies which could not only neu-
tralize one influenza virus strain but several. Indeed, by now,
antibodies have been detected which can neutralize several
influenza A subtypes, all subtypes within one of the two
phylogenetic groups of influenza A viruses, viruses of both
phylogenetic groups or provide protection against all influ-
enza A and B viruses [18,53,89]. Although these antibodies are
found infrequently and in low amounts after infection or
vaccination, their existence has encouraged the search for
vaccines capable of inducing such bNAbs. Many of the
bNAbs were found to target the HA stem region which is
much more conserved than the HA head region. Approaches
to focus vaccine-induced antibody responses on the stem
include sequential immunization with vaccines containing dif-
ferent HA molecules, sequential immunization with chimeric
HA molecules carrying different irrelevant heads and the same
stem, and mini-HA constructs consisting of only the HA stem
region (for a recent review see [90]). Several of these
approaches are currently tested in clinical trial, and the results
are awaited eagerly.
The second important observation was that influenza-spe-
cific antibodies do not necessarily have to interfere with the
infection process as such but can rather use other effector
mechanisms like ADCC, ADCP, or ADCD to counteract viral
infection. Non-neutralizing antibodies had earlier been largely
overlooked, partly because the assays needed to detect them
require specific material (e.g. NK cells, macrophages) and are
tedious and often not well reproducible. Influenza-specific
antibodies which work via ADCC, ADCP, or ADCD can target
different viral proteins including conserved ones like NP and
M2 and can thus be highly cross-reactive. This opens new
possibilities for the design of broadly protective vaccines. In
this context, it is very important to realize that ADCC-, ADCP-,
and ADCD-exploiting antibodies need to interact via their Fc
part with Fc receptors on effector cells or with complement.
Accordingly, the class and subclass of the vaccine-induced
antibodies will become important as it will determine their
biological function. In particular, IgG3 should be induced as
this antibody subclass has high affinity to activating Fcγ recep-
tors and high complement-fixing activity [57,59].
The third observation is that the B-cell response to influ-
enza infection but also to vaccination consists to a rather large
extent of pre-existing cross-reactive antibodies rather than of
newly induced strain-specific antibodies [21,54,91]. Thus,
rather than activating naïve B-cells, infection and vaccination
re-activate memory B-cells which were induced by previous
encounter of influenza antigens. The phenomenon has been
addressed as ‘original antigenic sin’ thus emphasizing a pos-
sible detrimental role of pre-existing immunity. Yet, recently
the term ‘antigenic seniority’ has been coined to underline
that pre-existing immunity can have both positive and nega-
tive effects on the response to vaccination [77]. In any case,
the effects of pre-existing immunity imply that infection and
vaccination history will have a major impact on the response
to any new influenza vaccination. While pre-existing memory
B-cells might be disadvantageous for induction of neutralizing
antibodies to the receptor binding site of new variants of HA,
they may be highly advantageous to achieve effective
antibody responses against conserved influenza antigens; anti-
bodies which work via neutralization of the HA stem or via
non-neutralizing effector mechanisms. A better knowledge of
the role of pre-existing influenza-specific immunity on the
response to vaccination in its entire breadth may allow for
the design of vaccines which optimally exploit pre-existing
immunity. Such a vaccine could, for example, be tailored to
specific target groups, in particular young children and the
elderly. Interestingly, already in 1960 Thomas Francis Jr sug-
gested that OAS could be exploited to our advantage by
vaccinating children early in life with several influenza stains
so that natural infections later in life would serve to broaden
the vaccine-generated immunity [7].
6. Five-year view
The insight that antibodies not detected in current neutra-
lization assays and non-neutralizing antibodies are able to
confer protection against influenza will stimulate the devel-
opment of new assays with which these antibodies can be
reliably measured. Application of these assays will allow us
to determine the levels of these antibodies in the general
population and how these levels change upon vaccination.
Non-neutralizing and non-classical neutralizing antibodies
will be further studied and their targets and mechanisms
of action investigated. Eventually, we will be able to under-
stand the role of these antibodies as well as their interplay
in providing protection. Identification of the most frequent
or most potent antibodies prevailing in absence of neutra-
lizing antibodies will allow designing vaccines capable of
inducing these antibodies and will get us closer to broadly
protective vaccine. The concept of antigenic seniority and
the impact that this phenomenon has on the boosting/gen-
eration of influenza-specific antibodies will be further inves-
tigated. Eventually, integration of knowledge in both fields,
non-neutralizing or non-classical neutralizing antibodies and
the role of pre-existing antibody responses, will allow us to
design novel immunization strategies capable of providing
broad and strong protection and optimized for different
vulnerable groups of the general population.
Key issues
● The ability of a vaccine to elicit antibodies is currently
mainly measured by means of hemagglutination inhibition
(HAI) or microneutralization (MN) assays. This practice has
resulted in overlooking of non-neutralizing antibodies and
antibodies, which neutralize in a non-classical way.
● Classic neutralizing antibodies interfere with virus binding
to its cellular receptor. Other ways of neutralization are
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inhibition of fusion, cross-linking of budding virions at the
cell surface and prevention of NA-dependent release of
newly formed virus particles.
● Non-neutralizing antibodies have been demonstrated to be
able to confer protection against influenza virus via ADCC,
ADCP, and ADCD. These antibodies should, therefore, be deter-
mined upon vaccination in addition to HAI/MN antibodies and
their role in protection should be further investigated.
● Future research is needed to unravel the mystery behind the
impact of pre-existing immunity on the boosting/generation
of influenza-specific antibodies following vaccination.
Acquired knowledge from these studies will allow us to
eventually exploit pre-existing immunity to our advantage.
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